"The primary outcome is simply to show that Brilacidin can also be delivered to targeted areas of the colon."
Per this morning's note the targeted area is the colon itself. "We believe that targeted delivery to the colon is part-and-parcel to the potential future success of Brilacidin as a new oral inflammatory bowel disease drug."
The Company hasn't said that their purpose is "to show that Brilacidin can also be delivered to targeted areas of the colon". BDD hasn't claimed that ability as far as I know. And that's why I've asked this question more than once (albeit in different ways): Is it the hope of the Company to be able to treat the entire colon, thereby treating the diseased area therein, or to treat the diseased area itself?
Feel free to substitute "do you expect" for "Is it the hope of" in the above.